Finally, Piperno and colleagues also showed in a group of patients with chronic hepatitis C that those who responded to interferon had lower hepatic iron concentrations than those who did not.7 Other investigators have not found a difference in HIC between responders and non-responders, but rather have identified a significant difference in hepatic cellular iron distribution in non-responders to interferon compared with responders.8 Using detailed histomorphometric analysis in a small series of patients, Barton et al showed that non-responders to interferon had predominant distribution of iron in Kupffer cells compared with responders.8 As all of these studies were performed retrospectively, there is the possibility of some degree of selection bias, although this seems unlikely given the number of times this observation has now been made.
These findings have led to the consideration of whether patients might benefit by being depleted of excess iron stores by repeated therapeutic phlebotomy before treatment with interferon or to improve response rates in previous non-responders. One small study from Japan with a heterogenous group of patients showed a significant reduction in serum concentrations of alanine aminotransferase (ALT) in all patients who were made iron deficient.9 Additionally, several other reports of phlebotomy therapy in chronic hepatitis C have been published, consistently demonstrating a significant reduction in serum ALT concentrations; however, no consistent evidence of a change in hepatitis C virus (HCV) RNA levels has been shown. 7 10 11 The precise reasons for these associations between hepatic iron metabolism and chronic hepatitis C or responsiveness to treatment with interferon, or both, are poorly understood. A variety of immunological and virological effects of iron overload or iron deficiency, or both, are known, but it is not clear that any of these relate to the immunopathological manifestations seen in chronic hepatitis.6 8 12 Alternatively, patients with chronic hepatitis may have altered mechanisms of cellular iron uptake or hepatic iron deposition, or both. 6 In this issue, Boucher and colleagues (page 115) have provided some additional interesting insights into the relation between hepatic iron metabolism and chronic hepatitis C. In their study, 55 patients were treated with interferon-ox for six months and were evaluated for HIC and cellular distribution of hepatic iron before and six months after therapy was completed. They found no difference in HIC between non-responders and responders. However, they did identify a relation between HIC and histological evidence of inflammatory activity such that the iron load was higher in those patients with the greatest degree of histological inflammatory activity. Surprisingly, HIC decreased significantly following treatment. This was related to iron depletion in mesenchymal cells and was apparent regardless of whether patients responded to interferon (ALT normalisation, loss of HCV RNA) or not. These findings suggest that the presence of increased hepatic iron stores in patients with chronic hepatitis may be present predominantly as a result of the degree of inflammatory activity, presumably correlating cell injury or necrosis, or both, with subsequent hepatocyte phagocytosis by Kupffer cells resulting in progressive increases in Kupffer cell iron loading. Of greater interest, however, is the loss of hepatic iron deposits as a result of the loss of iron in mesenchymal cells with interferon treatment regardless of whether or not patients had a response. Potential mechanisms whereby this could occur are discussed by the authors and include up-regulation of transferrin receptor expression in macrophages induced by inflammation, with an anti-inflammatory effect of interferon presumably down-regulating this expression. Alternatively, the possibility of a shift of iron from the liver to extrahepatic sites such as the bone marrow was considered, although this mechanism was felt to be unlikely.
Another explanation of theoretical interest relates to the recent discovery of an MHC class 1-like gene (HLA-H) thought to be responsible for haemochromatosis. 13 Patients homozygous for the predominant mutation (Cys282Tyr) presumably have failure to express HLA-H on the surface of cells, resulting in increased gastrointestinal iron absorption and subsequent deposition of iron in hepatocytes and other parenchymal cells in the body. It is known that interferon up-regulates the expression of MHC class 1 proteins and therefore, it could be that interferon results in a net decrease in absorption or uptake, or both, of iron into the liver providing an explanation for the observations made by Boucher et al.
Although the mechanisms whereby the interactions between iron metabolism and chronic viral hepatitis occur are still largely unknown, it is increasingly apparent that there is a definite relation between these two entities. 
